Clinical Trial Update: A Study of SU11248 In Patients With Metastatic Breast Cancer Who Have Failed Selected Other Therapies. [Phase 2]

View source ↗

Summary

A Phase 2 study evaluated SU11248 (sunitinib malate) in patients with metastatic breast cancer who had failed other therapies; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: Pfizer | Conditions: Breast Neoplasms | Phase 2 | Status: COMPLETED